What this means
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, have transformed the pharmacological treatment of obesity. While highly efficacious in promoting weight loss, these drugs also induce substantial reductions in lean mass, raising concerns for skeletal muscle loss, particularly in older individuals vulnerable to sarcopenia.
A plain-English summary is on its way. Until then, this is the start of the authors' own summary.
- Who it was tested in
- Not stated
- Kind of research
- A study
The science
- Original title
- Aging exacerbates muscle loss induced by semaglutide treatment in female mice.
- Authors
- Rout S, Karasawa T, Moore ER et al.
- Journal
- bioRxiv : the preprint server for biology
- Published
- Nov 20, 2026
- Study type
- Study
- PMID
- 43059920 ↗
Abstract
Background
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, have transformed the pharmacological treatment of obesity. While highly efficacious in promoting weight loss, these drugs also induce substantial reductions in lean mass, raising concerns for skeletal muscle loss, particularly in older individuals vulnerable to sarcopenia. Nevertheless, there are currently no published human studies that investigated the effects of GLP-1RAs on skeletal muscle mass using gold standard methods. Meanwhile, studies in young mice demonstrate that skeletal muscle loss induced by GLP-1RAs might not be a major concern. The purpose of the current study was to investigate the effects of semaglutide on skeletal muscle mass and strength in aged mice.
What they did
Eighteen-month-old male and female C57BL/6J mice were fed a high-fat diet (HFD) for 12 weeks to induce obesity. At 21 months of age, mice received daily subcutaneous injections of vehicle or semaglutide (3 or 30 nmol/kg) for 3 weeks. Body composition was assessed weekly by nuclear magnetic resonance (NMR) spectroscopy. After 3 wks, mice were terminated to assess masses of individual organs including skeletal muscle. Skeletal muscle force-generating capacity was assessed by ex vivo electrical stimulation-induced contraction. Myofiber cross-sectional area and fiber-type composition were also assessed.
What they found
Semaglutide induced dose-dependent weight loss in both sexes, with reductions of 11.3% and 20.2% in males and 21.1% and 26.1% in females receiving 3 or 30 nmol/kg dose, respectively. There was a substantial sex-difference in the loss of lean mass, with relatively minor reductions in males (2.3% and 6.6%) and greater loss in females (8.6% and 8.3%). Skeletal muscle mass was largely preserved in males but females exhibited greater muscle mass loss, including 14.2% reduction in quadriceps mass at 30 nmol/kg of semaglutide treatment. In contrast, skeletal muscle force-generating capacity was not compromised in semaglutide-treated females, while males exhibited 19.2% reduction in force generating capacity of the extensor digitorum longus (EDL) muscles at the 30 nmol/kg dose. Unlike young mice, semaglutide treatment may induce meaningful loss in skeletal muscle mass in aged female mice and muscle strength in aged male mice. These findings highlight the importance of considering age as a potential factor that may negatively influence muscle mass and function in humans treated with GLP-1RAs. Clinical studies examining the influence of pharmacological weight loss on skeletal muscle mass and strength should consider both age and sex as a potentially important determinant of these outcomes.
The authors' abstract, grouped under plain headings from its own section labels.
Rout S, Karasawa T, Moore ER et al. Aging exacerbates muscle loss induced by semaglutide treatment in female mice. bioRxiv : the preprint server for biology. 2026. doi:10.64898/2026.11.11.766063. PMID: 43059920. https://pubmed.ncbi.nlm.nih.gov/43059920/
Related research
Review compares six collagen fillers for face loss linked to weight-loss drugs
This review looked at 43 studies of six types of collagen-building fillers and how each may signal cells. It does not show which filler works best, and no study tested people on these drugs.
Aging exacerbates muscle loss induced by semaglutide treatment in female mice
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, have transformed the pharmacological treatment of obesity.
Weight management in people with HIV.
Excess weight gain in people with HIV is now recognised as a common risk associated with the use of guideline-recommended antiretroviral therapy, such that nearly 50% of people with HIV are living with comorbid obesity.
A skin serum showed visible improvements in older women over 12 weeks
Women aged 45 and older used a facial serum twice a day for 12 weeks. Experts and participants saw changes in fine lines, wrinkles, and skin hydration. This study had no comparison group, so it cannot show the serum caused the changes.
Doctors' group offers a guide for using weight-loss drugs like GLP-1 in older adults
Experts wrote a guide on weighing benefits and risks, such as muscle loss, when older adults take these drugs. It is advice built from example patient cases, not a new study testing the drugs.
Lessons from dog lifespan therapeutics for their human companions.
The growing evidence that existing cardio-renal-metabolic therapies, such as GLP-1 receptor agonists and SGLT2 inhibitors, confer all-cause mortality benefits has positioned them as the first wave of potential…
See all research on GLP-1 drugs →
